Mipasetamab is an IgG1kappa antibody targeting to AXL, a tyrosine kinase receptor and an TAM Receptor. Mipasetamab involves in synthesis of ADCT-601 (Mipasetamab uzoptirine), an AXL-targeted antibody-drug conjugate (ADC). ADCT-601 has anti-tumor activity[1].
Molecular Weight:
(145.6 kDa)
Purity:
98.26
CAS Number:
[2361055-48-1]
Target:
ADC Antibody,TAM Receptor
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted